Vytorin

Vytorin is an oral combination drug containing two lipid-lowering agents with complementary mechanisms of action. It consists of ezetimibe, a selective inhibitor of intestinal cholesterol and phytosterol absorption that targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, and simvastatin, a statin that inhibits hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase to block endogenous cholesterol synthesis. Together, these agents reduce total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), while increasing high-density lipoprotein cholesterol (HDL-C). Vytorin is indicated as adjunctive therapy to diet for primary hyperlipidemia or mixed hyperlipidemia and for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments[1][7][6][3].

Brand names

Vytorin

Other names

ezetimibe/simvastatinsimvastatin/ezetimibeezetimibe; simvastatinsimvastatin;ezetimibe